The Truth About Reptides

A sourced critique of Reptides' pivot from an RUO peptide vendor direction into a peptide information platform, and why transparency around that change matters.

---

Why I am writing this

I want to lay out why Reptides has bothered me for a while, because I think there is a broader point here about transparency, rebrands, and who gets to present themselves as being above the messier parts of the RUO peptide space.

This is not about saying people cannot change direction.

People can pivot. People can realize something is legally risky. People can decide selling RUO peptides is not worth it. Honestly, that may even be the smart move.

But if a project starts in one lane, later rebrands into a more respectable information platform, and then takes a moral high-ground tone toward the same type of vendor behavior it once participated in, I think people are allowed to ask questions.

That is the issue I have with Reptides.

The short version

From public posts by @ogsvg, Reptides was not always just a peptide research reference or wiki-style platform.

The account explicitly described Reptides as having been an RUO vendor. It also described people buying from him, building the store quickly, using PayPal because Stripe would not accept him, sourcing from China, and later stopping because of legal/regulatory risk.

That matters because Reptides is now presented much more as an evidence-based peptide information platform.

Again, the pivot itself is not the issue.

The issue is transparency around the pivot.

If the public explanation had simply been:

I tried building an RUO peptide vendor. I realized the sourcing, testing, payment, and legal risk were not worth it. So I rebuilt Reptides into an information platform instead.

I would respect that.

What bothers me is the combination of:

• acknowledged RUO vendor history
• public descriptions of real store infrastructure, product listings, and revenue
• later repositioning into a cleaner information/reference role
• criticism of grifters and low-barrier peptide vendors
• later affiliate-program and product-development language
• and a lack of clear, front-and-center explanation of that transition

Exhibit 1: Reptides publicly described building a peptide store

On April 12, @ogsvg described building a full e-commerce store with checkout, user accounts, an admin panel, affiliate tracking, and 46 products.

That matters because this was not framed as a vague idea, a private prototype, or a purely educational experiment.

It was described as a functioning store buildout with product listings, checkout, account infrastructure, and affiliate tracking.

That is a very different starting point than a site that was always only an information platform.

Exhibit 2: The store was promoted as selling 99%+ compounds

On April 13, the account responded to a thread about peptide pricing by saying Reptides sold the same 99%+ compounds for less because it did not have the overhead of larger vendors.

Again, this is important context.

The later Reptides positioning is built around being an independent research/information platform, but the earlier public language described Reptides in vendor terms: selling compounds, competing on price, and differentiating against other peptide sellers.

Exhibit 3: Reptides later said it generated revenue as a research peptide company

On April 17, @ogsvg said he spent two weeks building a research peptide company, found a supplier, had COAs, and generated revenue before even receiving full inventory from China.

This is one of the cleanest pieces of the timeline.

If a later post says the only money Reptides ever made came from selling information and content, then this earlier revenue claim needs to be reconciled.

Maybe the explanation is that Reptides now means the current post-pivot platform.

Maybe those early sales were small enough that he does not consider them material.

Maybe he refunded them, never fulfilled them, or is drawing some other distinction.

But the public record still creates a real tension: one post says revenue came from a research peptide company phase, while another later post frames Reptides revenue as information/content only.

Exhibit 4: Reptides was openly described as an RUO vendor

The May 6 post makes the vendor history even more explicit.

In it, @ogsvg says he “did this with Reptides,” says people bought from him, describes building the store in two days, says Stripe would not accept him, and says he found a Chinese peptide supplier with COAs and a U.S. warehouse.

He also says the reason he stopped was risk around future FDA enforcement, and that the long legal game is selling information rather than the actual peptides.

This is the core of my criticism.

It is not just that Reptides “looked like” a vendor. The account directly described the earlier version of Reptides as a peptide-selling operation.

That changes how the later positioning reads.

Exhibit 5: RUO peptide sites framed as a broader decentralized medicine shift

Two days later, the same account framed RUO peptide websites as part of a larger unwinding of a system that funnels money upward.

The post describes average people using software tools to ship what it calls a facade of a compounding pharmacy from home.

This is not a neutral position. It reads as a defense of the broader phenomenon, or at least a sympathetic explanation of why people are doing it.

That is fine as commentary.

But it makes the later legal-risk posture and reference-platform positioning more important to explain clearly.

Exhibit 6: Reptides later drew a legal line around dosing guidance

On May 13, @ogsvg explained that Reptides does not sell dosing guides for retatrutide or other peptides not FDA-approved for the uses people discuss online.

The reason given was legal risk: publishing dosing guidance for unapproved drugs could be interpreted as unauthorized practice of medicine.

I actually think this is a reasonable line to draw.

I also think it supports the larger point: Reptides clearly made a legal and operational decision about what it wanted to become.

That decision should be explained as a pivot, not buried behind a cleaner current identity.

Exhibit 7: Criticism of grifters and low-barrier peptide vendors

On May 15, the account criticized the peptide boom for attracting people who think they are the next Steve Jobs, and said it is not difficult to code a site and find a decent peptide supplier.

I do not disagree with the substance.

The RUO peptide market has absolutely attracted people who see a low barrier to entry and a fast money opportunity.

But this is where the tone starts to matter.

If you previously built the same kind of operation, sourced from China, took orders, and then pivoted away because of legal risk, you can still criticize the space. But you should do it with that history fully visible.

Otherwise it reads like distance created after the fact.

Exhibit 8: Peptide Supply blocking Reptides when it was an RUO vendor

On May 24, the account said Peptide Supply blocked him back when “reptides was an RUO vendor” and he was spamming their comments with his page.

This is another direct acknowledgment.

It also matters because it undercuts any attempt to frame the earlier vendor direction as a vague experiment that never really went public.

By his own wording, Reptides was an RUO vendor, and he was actively promoting it.

Exhibit 9: Reptides later defended its own affiliate program

On June 22, @ogsvg responded to a post saying Reptides’ affiliate program was live.

The response distinguished Reptides’ program from normal affiliate selling by comparing it more to a software sales representative role responsible for nurturing and expanding the Reptides brand.

This is another reason the later anti-affiliate / integrity framing should be more precise.

There is a difference between saying:

We do not take vendor affiliate money.

and saying:

Reptides has no affiliate model.

Those are not the same thing.

If Reptides has, or had, an affiliate program for its own platform, then the more accurate claim is not “zero affiliate.” It is “we do not participate in outside vendor affiliate promotion.”

That distinction matters.

Exhibit 10: Reptides later described working on a peptide product

On June 26, the account said Reptides was working on a peptide hair serum and gathering ingredients for a prototype.

This does not prove Reptides is currently selling RUO peptides.

It does, however, complicate any broad claim that Reptides will never sell peptide-related products.

If the actual position is “we do not sell RUO injectable peptides,” then say that.

If the position is “we may develop legal topical products but not RUO vendor products,” say that.

Precision matters because the public messaging around Reptides often leans heavily on trust, integrity, and being different from the rest of the space.

Exhibit 11: The later integrity framing

On June 29, Reptides posted that it had never been affiliated with anyone outside of Reptides, had never benefited financially from association with any single company, and that the only money Reptides made was from selling information and content on its platform.

The post ended with: “Integrity cannot be bought.”

I understand the point being made here.

It is a contrast against affiliate-driven vendor promotion and paid relationships in the peptide space.

But this is exactly why the older RUO vendor history matters.

If Reptides wants to position itself as an integrity-first, evidence-based information platform, then the earlier vendor chapter should be easy to find and easy to understand.

The money claim is the part that deserves the hardest scrutiny.

The April and May posts describe:

• a full e-commerce store
• checkout and account infrastructure
• affiliate tracking
• peptide product listings
• supplier sourcing
• payment processing
• actual buyers
• and generated revenue

So when the later claim says Reptides only ever made money from selling information and content, readers should ask what definition is being used.

Does that statement exclude the earlier vendor phase?

Does it mean the current Reptides platform only?

Does it mean no meaningful profit, even if sales occurred?

I do not know the answer, and that is the point. The clean integrity framing would be stronger if it accounted for the messy transition directly.

Exhibit 12: Reptides continues positioning against paid affiliate and sponsored peptide information

On July 7, Reptides again positioned itself against paid affiliate, sponsored, AI-slop peptide information, while saying the project has cost $10,000 so far and has a larger roadmap.

That may be true for the current platform.

But it also makes the historical clarity more important, not less.

If Reptides wants to be understood as a clean alternative to affiliate-driven peptide content, then the project should clearly separate:

• the old RUO vendor phase
• any early product sales or revenue
• the current information subscription business
• its own affiliate or sales-rep program
• and any future peptide-related product plans

Without that clarity, the messaging risks sounding cleaner than the actual timeline.

My actual criticism

My criticism is not:

• Reptides pivoted
• Reptides stopped selling peptides
• Reptides decided information was safer than product sales
• Reptides refuses to publish dosing guides

Those may all be reasonable decisions.

My criticism is this:

Reptides should be more transparent about the transition from RUO vendor to peptide information platform, especially when the account now comments critically on grifters, low-barrier peptide vendors, Chinese sourcing, and legal risk in the RUO space.

The history changes the tone.

It does not automatically invalidate the current project, but it does make transparency more important.

Why this matters beyond Reptides

The peptide space already has enough opacity.

There are vendors and creators with:

• unclear sourcing
• vague COA claims
• disappearing pages
• quiet rebrands
• affiliate relationships presented like neutral recommendations
• product claims dressed up as research commentary
• and “community resource” branding that hides financial incentives

That is exactly why I care about this.

If someone is building a peptide reference project, wiki, pricing site, review platform, newsletter, or vendor board, the standard should be higher.

That includes me too.

PeptideBenchmark has affiliate relationships. I disclose them. If I accept a review sample, I disclose it. If I change scoring logic, I try to explain it. If I add sponsored placements, those placements need to be labeled.

I am not saying I am above scrutiny.

I am saying the same transparency standard should apply across the board.

What Reptides could have done differently

This would be much less of an issue if Reptides had a clear public post or page saying something like:

Reptides originally explored RUO peptide sales. We stopped because the sourcing, payment, testing, and regulatory risk were not aligned with the long-term project. Reptides is now an information platform focused on peptide research data, and we do not sell RUO peptides or dosing guidance.

That would be direct.

That would be credible.

That would make the later integrity framing stronger, not weaker.

The problem is not the pivot.

The problem is the memory hole around the pivot.

Bottom line

Reptides may be useful as a peptide information platform.

But the public record matters.

The account behind it directly described Reptides as an RUO vendor, described people buying from it, described sourcing from China, described payment processor issues, and described stopping because the legal risk was too high.

That history should be part of how people understand the current project.

People can change direction.

They should just be honest about what changed.